https://www.selleckchem.com/pr....oducts/gilteritinib-
The median survival time after initial therapy for patients with novel agents was 56.4 months and 3-year overall survival (OS) was 70.4%. In multivariate analysis, ISS stage I/II disease and PR or better response to initial treatment, and autologous stem cell transplantation (ASCT) were identified as independent prognostic factors for overall survival (OS).Despite its importance in cardiovascular diseases and engineering applications, turbulence in pulsatile pipe flow remains little comprehended. Important advances have bee
Like
Comment
Share
